BIOMEA FUSION INC. - COMMON STOCK

Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023

02 Nov 2023 09:05:57 By Nasdaq GlobeNewswire

Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights

30 Oct 2023 16:01:20 By Nasdaq GlobeNewswire

Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)

17 Oct 2023 08:30:41 By Nasdaq GlobeNewswire

Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes

05 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study

28 Sep 2023 08:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer

31 Aug 2023 08:30:41 By Nasdaq GlobeNewswire

Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights

31 Jul 2023 16:01:28 By Nasdaq GlobeNewswire

Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 Demonstrated a 90% Response Rate and 70% Maintained or Improved Time in (Normal Glucose) Range, While Off-Treatment

23 Jun 2023 21:54:37 By Nasdaq GlobeNewswire

Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023

20 Jun 2023 16:30:19 By Nasdaq GlobeNewswire

Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights

02 May 2023 16:01:20 By Nasdaq GlobeNewswire

Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

01 May 2023 08:30:00 By Nasdaq GlobeNewswire

Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June

19 Apr 2023 08:30:00 By Nasdaq GlobeNewswire

Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting

13 Apr 2023 16:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

13 Apr 2023 09:00:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock

29 Mar 2023 23:15:39 By Nasdaq GlobeNewswire

Biomea Fusion Announces Proposed Public Offering of Common Stock

29 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

28 Mar 2023 16:02:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28

28 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET

23 Mar 2023 08:00:02 By Nasdaq GlobeNewswire

Biomea Fusion To Participate In Upcoming Investor Events

02 Mar 2023 08:30:47 By Nasdaq GlobeNewswire